X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs ASTRAZENECA PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA PROCTER & GAMBLE HEALTH/
ASTRAZENECA PHARMA
 
P/E (TTM) x 53.0 61.4 86.3% View Chart
P/BV x 4.8 17.3 27.7% View Chart
Dividend Yield % 9.9 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
ASTRAZENECA PHARMA
Mar-18
PROCTER & GAMBLE HEALTH/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5491,278 277.7%   
Low Rs1,301883 147.4%   
Sales per share (Unadj.) Rs511.4228.4 223.9%  
Earnings per share (Unadj.) Rs61.310.4 591.4%  
Cash flow per share (Unadj.) Rs74.016.3 455.2%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.898.8 939.3%  
Shares outstanding (eoy) m16.6025.00 66.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.7 100.3%   
Avg P/E ratio x39.6104.2 38.0%  
P/CF ratio (eoy) x32.866.4 49.3%  
Price / Book Value ratio x2.610.9 23.9%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,25727,008 149.1%   
No. of employees `0001.11.4 83.6%   
Total wages/salary Rs m1,3131,535 85.5%   
Avg. sales/employee Rs Th7,486.74,210.9 177.8%   
Avg. wages/employee Rs Th1,157.61,132.2 102.2%   
Avg. net profit/employee Rs Th897.2191.1 469.5%   
INCOME DATA
Net Sales Rs m8,4905,710 148.7%  
Other income Rs m244123 199.1%   
Total revenues Rs m8,7345,833 149.7%   
Gross profit Rs m1,482463 320.1%  
Depreciation Rs m211147 143.3%   
Interest Rs m00-   
Profit before tax Rs m1,514438 345.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m563179 314.4%   
Profit after tax Rs m1,017259 392.7%  
Gross profit margin %17.58.1 215.3%  
Effective tax rate %37.140.8 90.9%   
Net profit margin %12.04.5 264.1%  
BALANCE SHEET DATA
Current assets Rs m15,3433,209 478.1%   
Current liabilities Rs m1,9602,070 94.7%   
Net working cap to sales %157.620.0 789.8%  
Current ratio x7.81.6 504.8%  
Inventory Days Days4972 67.4%  
Debtors Days Days2835 81.5%  
Net fixed assets Rs m1,209790 153.0%   
Share capital Rs m16650 332.0%   
"Free" reserves Rs m15,2352,419 629.7%   
Net worth Rs m15,4012,469 623.7%   
Long term debt Rs m00-   
Total assets Rs m17,5954,605 382.0%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.2 38.9%   
Return on assets %5.85.6 102.8%  
Return on equity %6.610.5 63.0%  
Return on capital %10.317.7 57.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,636300 546.3%   
Fx outflow Rs m4,3682,015 216.8%   
Net fx Rs m-2,732-1,715 159.3%   
CASH FLOW
From Operations Rs m-1,30488 -1,483.3%  
From Investments Rs m12,697-94 -13,565.4%  
From Financial Activity Rs m-301NA-  
Net Cashflow Rs m11,093-6 -194,612.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 0.3 6,066.7%  
FIIs % 1.0 15.7 6.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 9.1 319.8%  
Shareholders   28,591 12,856 222.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Dividend Stocks Amid Volatile Stock Markets; US-China Trade War and More(Podcast)

The market, which has been caught in the grip of the bears, gave a negative yearly return for first time in last eight years.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

7 Stocks to Buy in Today's Difficult Market(The 5 Minute Wrapup)

Aug 5, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

My Top 3 Dividend Millionaire Stocks(Profit Hunter)

Aug 7, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Aug 16, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS